繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

周六报道称,Alumis的ESK-001在II期银屑病研究中在第52周表现出持续的PAS 90和PAS 100反应

2025-03-10 15:43

  • ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupus
  • Phase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing clinical responses through week 52 on PASI 90, PASI 100, and sPGA 0
  • ESK-001 was generally well-tolerated at one year, with no new safety findings
  • Data further support ESK-001's potential to offer a highly differentiated and best-in-class treatment option for people with moderate-to-severe plaque psoriasis
    • Phase 3 ONWARD program ongoing with topline data expected in Q1 2026

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。